cagrilintide
Cagrilintide, explained.
Cagrilintide is the long-acting amylin analog studied as the amylin half of the CagriSema™ combination. PepEasy offers a neutral, cited place to understand what it is and how the research describes it.
Educational only — not medical advice. PepEasy never recommends a dose.
Cagrilintide is a long-acting, lipidated amylin analog developed by Novo Nordisk and studied in the context of weight management. Given in research as a once-weekly subcutaneous injection, it is designed to mimic the gut-brain hormone amylin, which influences appetite and gastric emptying. It is best known as the amylin component studied alongside semaglutide (CagriSema™) and is not FDA-approved.
What cagrilintide is
Cagrilintide is a synthetic analog of amylin — a peptide hormone co-secreted with insulin by the pancreas that helps signal fullness after eating. The native hormone has a half-life of only minutes and tends to clump (aggregate), which makes it unsuitable as a drug. Cagrilintide is the engineered version: its sequence is stabilized against aggregation and a fatty-acid chain is attached (lipidation) so it binds albumin in the blood and clears slowly. The result is a long-acting molecule with a half-life of roughly 180 hours. It was developed by Novo Nordisk and has been studied both on its own and, more prominently, combined with the GLP-1 drug semaglutide in a fixed-dose product the company calls CagriSema™. Cagrilintide is an investigational drug: it is not approved by the FDA as a standalone medicine, and the CagriSema™ combination was submitted to the FDA in December 2025 and is under review — not yet cleared.
How cagrilintide is thought to work
Amylin acts alongside insulin and GLP-1 as a satiety signal. It binds amylin receptors — heterodimers built from the calcitonin receptor paired with receptor-activity-modifying proteins (RAMP1, 2, or 3) — that are concentrated in brain regions associated with appetite, including the area postrema and hypothalamus. In the published literature, activating them is associated with three effects: reduced hunger and food intake, a slower rate of stomach emptying, and a dampened post-meal glucagon surge. Recent mechanistic work points to brain amylin receptors AMY1 and AMY3 as the key sites studied for cagrilintide's effect on weight. Because amylin and GLP-1 act through different but complementary pathways, pairing cagrilintide with semaglutide is the rationale behind CagriSema™. This is mechanism as described in the published literature, not a promise of a result for any individual.
Areas of research interest
- Weight management — the primary and most-studied research context; cagrilintide has been investigated in phase 2 and phase 3 obesity trials.
- As the amylin component of CagriSema™ — studied combined with semaglutide in research on appetite signaling.
- Appetite and gastric-emptying research — slowed gastric emptying and satiety signaling are the mechanisms investigated.
- Type 2 diabetes research adjacency — CagriSema™ was studied in adults with type 2 diabetes (REDEFINE 2), examining glycemic measures alongside weight.
- As a non-GLP-1 mechanism — investigated as an amylin-pathway agent rather than (or alongside) a GLP-1 drug. None of this is medical guidance; these are simply the contexts in which cagrilintide appears in research and discussion.
Side effects & safety
In trials, the dominant reported side effects are gastrointestinal, tracking with the mechanism (slowed gastric emptying). In the published phase 2 trial, nausea was reported to rise with higher amounts administered, with constipation, vomiting, and injection-site reactions also reported. These effects are described as usually mild to moderate, tending to peak during each escalation step and ease over following weeks. In the CagriSema™ phase 3 trials, GI events were again the most common reason participants felt unwell. Longer-term and rare-event safety data are still accumulating because the drug is investigational; the full risk picture is not as established as for long-marketed medicines. Anyone with questions about cagrilintide should discuss GI tolerability, possible interactions, and personal history with a qualified licensed provider — this section summarizes published findings and is not a safety clearance.
Cagrilintide vs related peptides
| Cagrilintide | Semaglutide | Tirzepatide | |
|---|---|---|---|
| Class | Amylin analog | GLP-1 agonist | GIP/GLP-1 dual agonist |
| Primary signal | Amylin (satiety) | GLP-1 (satiety/insulin) | GIP + GLP-1 |
| Dosing route | Subcutaneous | Subcutaneous | Subcutaneous |
| FDA approved (weight) | No (investigational) | Yes (Wegovy™) | Yes (Zepbound™) |
| Often combined with | Semaglutide (CagriSema™) | — | — |
How PepEasy helps
Learn it
Plain-language, cited explanations of what cagrilintide is, how the amylin pathway is thought to work, and what the phase 2/3 and CagriSema™ trials actually reported — so you can ask better questions when you talk to a qualified licensed provider.
Understand the research
Neutral, cited summaries of the published literature in one place — so the science is clear. PepEasy never recommends a dose and is not medical advice.
Frequently asked
What are the side effects of cagrilintide?+
In trials, the most commonly reported are gastrointestinal: nausea (reported to rise with higher amounts administered), constipation, vomiting, and injection-site reactions. They are described as usually mild to moderate, tending to peak during each escalation step, then ease. Because the drug is investigational, long-term and rare-event safety data are still being collected. This is a summary of published findings, not medical advice.
Is cagrilintide a steroid?+
No. Cagrilintide is a peptide — a synthetic analog of the gut-brain hormone amylin. It has nothing to do with anabolic steroids or corticosteroids. It is studied as an activator of amylin receptors in the brain associated with fullness, not hormonal pathways like testosterone or cortisol.
What is cagrilintide compared to or paired with?+
It is most often studied paired with semaglutide (a GLP-1 drug) in the combination Novo Nordisk calls CagriSema™. Compared to semaglutide or tirzepatide, cagrilintide is a different mechanism (amylin rather than GLP-1/GIP), which is the rationale for studying it combined with, rather than replacing, a GLP-1.
Is cagrilintide FDA approved?+
No. Cagrilintide is not approved by the FDA as a standalone medicine. The CagriSema™ combination (cagrilintide plus semaglutide) was submitted to the FDA in December 2025 and is under review in 2026 — submitted is not approved. Material sold as cagrilintide today is typically labeled research-use-only and not intended for human use.
Everything peptides, made easy.
Join PepEasy and get the tools, the knowledge, and the care — in one place.
Explore more